<DOC>
	<DOCNO>NCT02160951</DOCNO>
	<brief_summary>This multi-center , open-label , dose escalation , Phase 1 study oral LGH447 Japanese patient relapse and/or refractory multiple myeloma standard effective treatment option exist . The study consist dose escalation part estimate maximum tolerate dose and/or recommend dose expansion dose expansion part ass safety preliminary anti-cancer activity LGH447 maximum tolerate dose and/or recommend dose expansion .</brief_summary>
	<brief_title>Dose Escalation Study LGH447 Japanese Patients With Relapsed and/or Refractory Hematologic Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<criteria>Confirmed diagnosis relapse and/or refractory MM standard effective treatment option exist . Uncontrolled cardiovascular condition , include ongoing cardiac arrhythmia , congestive heart failure , angina , myocardial infarction within past 6 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Multiple Myeloma ,</keyword>
	<keyword>Phase I ,</keyword>
	<keyword>PIM ,</keyword>
	<keyword>Japanese patient ,</keyword>
	<keyword>LGH447</keyword>
</DOC>